NRX Pharmaceuticals ernennt Joseph M. Casper zum Chief Operating Officer

Reuters06:16
NRX Pharmaceuticals ernennt Joseph M. Casper zum Chief Operating Officer

NRX Pharmaceuticals Inc. hat die Ernennung von Joseph M. Casper zum Chief Operating Officer mit Wirkung zum 27. Januar 2026 bekannt gegeben. Casper bringt 35 Jahre Erfahrung in der Gesundheitsbranche mit und war zuvor in leitenden Positionen unter anderem bei Deloitte, First Consulting Group, Kaiser Permanente und Anthem tätig.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-002682), on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment